Centralized Pan-Middle East Survey on the Under-treatment of Hypercholesterolemia, Sub-study for the Gulf States (CEPHEUS)

AstraZeneca

Status: Completed

Conditions: Hypercholesterolemia

Study type: Observational

Funder types: Industry

Identifiers

NCT01031277

SRP-CB-CRE-2006/01

NIS-GU-CRE-2009/1

Details and patient eligibility

About

The purpose of the study is to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III guidelines, overall and by country, to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III in the following sub-populations:

• Primary/secondary prevention patients.

• Patients with metabolic syndrome (according to NCEP III definition). And to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Third Joint European Task Force guidelines/national guidelines, in the survey population and in the following sub-populations:

  • Primary/secondary prevention patients.
  • Patients with metabolic syndrome.

Enrollment: 1,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Race
• On lipid-lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks.
• Subject must sign informed consent

Exclusion criteria

• Subjects who are unwilling or unable to provide informed consent.